These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 24939980)
1. Marginal structural Cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort. Karim ME; Gustafson P; Petkau J; Zhao Y; Shirani A; Kingwell E; Evans C; van der Kop M; Oger J; Tremlett H Am J Epidemiol; 2014 Jul; 180(2):160-71. PubMed ID: 24939980 [TBL] [Abstract][Full Text] [Related]
2. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642 [TBL] [Abstract][Full Text] [Related]
3. Dealing With Treatment-Confounder Feedback and Sparse Follow-up in Longitudinal Studies: Application of a Marginal Structural Model in a Multiple Sclerosis Cohort. Karim ME; Tremlett H; Zhu F; Petkau J; Kingwell E Am J Epidemiol; 2021 May; 190(5):908-917. PubMed ID: 33125039 [TBL] [Abstract][Full Text] [Related]
4. New natural history of interferon-beta-treated relapsing multiple sclerosis. Trojano M; Pellegrini F; Fuiani A; Paolicelli D; Zipoli V; Zimatore GB; Di Monte E; Portaccio E; Lepore V; Livrea P; Amato MP Ann Neurol; 2007 Apr; 61(4):300-6. PubMed ID: 17444502 [TBL] [Abstract][Full Text] [Related]
6. Estimating inverse probability weights using super learner when weight-model specification is unknown in a marginal structural Cox model context. Karim ME; Platt RW; Stat Med; 2017 Jun; 36(13):2032-2047. PubMed ID: 28219110 [TBL] [Abstract][Full Text] [Related]
7. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon. Bosca I; Coret F; Valero C; Pascual AM; Magraner MJ; Landete L; Casanova B Mult Scler; 2008 Jun; 14(5):636-9. PubMed ID: 18566027 [TBL] [Abstract][Full Text] [Related]
8. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort. Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792 [TBL] [Abstract][Full Text] [Related]
9. Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study. Shirani A; Zhao Y; Karim ME; Petkau J; Gustafson P; Evans C; Kingwell E; van der Kop ML; Oger J; Tremlett H Eur J Neurol; 2014 Jun; 21(6):835-44. PubMed ID: 24351059 [TBL] [Abstract][Full Text] [Related]
10. Scoring treatment response in patients with relapsing multiple sclerosis. Sormani MP; Rio J; Tintorè M; Signori A; Li D; Cornelisse P; Stubinski B; Stromillo Ml; Montalban X; De Stefano N Mult Scler; 2013 Apr; 19(5):605-12. PubMed ID: 23012253 [TBL] [Abstract][Full Text] [Related]
11. Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis. Rojas JI; Patrucco L; Miguez J; Besada C; Cristiano E Neurol Res; 2014 Jul; 36(7):615-8. PubMed ID: 24620963 [TBL] [Abstract][Full Text] [Related]